Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

BMS-193884 in development for heart failure

April 26, 1996

Class III antiarrhythmic presented by Japanese academics

April 26, 1996

GP-531 enters phase II

April 26, 1996

Antirestenosis agents reported by Fujisawa, Teijin

April 26, 1996

BMS-191095 in phase I for ischemia

April 26, 1996

Kanebo reveals new Na+/Ca2+ exchange inhibitor

April 26, 1996

FR-168888 shows myocardial protective effects in animals

April 26, 1996

Banyu's BR-1022 for angina

April 26, 1996

CP-060S suppresses myocardial cell calcium overload

April 26, 1996

Novel vasodilator MCC-134 reported by Mitsubishi Chemical

April 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.